Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 176 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Myeloid Leukemia, Philadelphia Positive Phase1, Phase2 China
France
Germany
Greece
Hungary
Italy
Japan
Netherlands
Poland
Russia
South Korea
Thailand
Turkey (Türkiye)
United States
View all

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

Relapsing Multiple Sclerosis Portugal

A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma

Spinal Muscular Atrophies Brazil

Study of Out of Specification for Tisagenlecleucel

B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma Phase3 Japan

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

Multiple Sclerosis Switzerland

Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

Multiple Sclerosis United States

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis Phase3 Argentina
Brazil
China
France
Germany
Greece
Israel
Italy
Japan
Netherlands
Spain
Switzerland
Turkey (Türkiye)
United Kingdom
United States
View all

Regulatory Post-Marketing Surveillance Study for Brolucizumab

Neovascular Age-related Macular Degeneration South Korea

A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

Graft-versus-Host Disease South Korea

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase2 France
Germany
Italy
Spain
United States
View all